Fresh IPOs are back in the spotlight, with the record SpaceX listing, a 19.2% first day surge, talk of Middle East peace helping crude oil prices, and stronger consumer sentiment all hitting the market at once. At the same time, stubborn inflation and a Federal Reserve that looks set to hold rates steady keep a lid on the easy-money story. Against this mix, some newly listed stocks have started to stand out. This article highlights 3 recent IPOs from the IPO Momentum Stocks screener. These stocks are closely tied to these headlines and may deserve a closer look from you.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

PicS (PICS)

Overview: PicS runs a broad digital finance app in Brazil that lets individuals and businesses handle instant payments, cards, loans, insurance and shopping inside a single wallet style platform.

Operations: PicS generates about R$11.7b in annual revenue in Brazil, with roughly R$11.7b from Consumer Banking, R$1.7b from Institutional clients, and smaller contributions from Small and Medium Sized Businesses and its Audiences and Ecosystem segment, partly offset by R$2.3b of inter segment adjustments.

Market Cap: R$1.4b

PicS offers a mix of high growth fintech economics and a still fresh IPO story, with earnings up very sharply in the past year and Q1 2026 profits and credit volumes ahead of guidance, while the stock trades on a single digit P/E and below some published fair value estimates. The business sits at the center of Brazil’s shift toward app based banking and secured digital credit, but depends heavily on external funding and a fast growing loan book, which raises questions about asset quality, capital and funding costs. Add in an IPO related class action focused on credit risk disclosure and this creates a complex setup that momentum focused investors may want to understand in detail before deciding how to view the current valuation and growth profile.

Earnings and credit volumes racing ahead of guidance while the stock sits on a single digit P/E can signal a story investors have not fully priced in, but the 3 key rewards and 2 important warning signs might reveal why this momentum could still surprise you

Once Upon A Farm PBC (OFRM)

Overview: Once Upon A Farm PBC is a Berkeley based food company focused on organic baby and kids nutrition, selling refrigerated and shelf stable pouches, meals, smoothies and soft baked bars through supermarkets, e commerce and direct to consumer channels.

Operations: Once Upon A Farm PBC generates around US$262.8m of revenue from Food Processing, all from the United States.

Market Cap: US$840.6m

Once Upon A Farm sits at the intersection of rising demand for organic, clean label kids nutrition and the distribution muscle that comes from more than 25,000 retail doors, cooler placements and a broad product range. Revenue forecasts above the wider US market and raised 2026 guidance to US$313m to US$323m highlight top line momentum, while Q1 2026 still showed a net loss of US$15.81m and the stock trades on a richer P/S than many food peers. Investors watching IPO momentum stories may focus on how management plans to turn faster growth, productivity projects and a purpose driven PBC model into sustainable profitability without over stretching on execution or valuation.

Growth at Once Upon A Farm looks like it is racing ahead of many food peers, but the valuation gap and ongoing losses raise tougher questions that the analyst forecasts for Once Upon A Farm PBC starts to unpack before a key twist in the story

20/20 Biolabs (AIDX)

Overview: 20/20 Biolabs develops AI powered blood tests aimed at catching multiple cancers and chronic diseases early, and also offers a longevity test that tracks inflammation, with its own CLIA lab that helps overseas diagnostics start ups enter the U.S. market.

Operations: The company generates about US$1.8m in revenue from Diagnostic Kits / Equipment, all from the United States.

Market Cap: US$10.2m

20/20 Biolabs sits at the intersection of AI, early cancer detection and longevity testing, with products like OneTest for Cancer now reaching firefighters in Vermont and Maryland programs that together are expected to add around US$1m of revenue in 2026. Yet this is still a very small, loss making business with limited revenue scale, a share price that has been highly volatile and less than one year of cash runway, so future funding is a key question. Recent licensing deals for PSA velocity and chronic kidney disease prediction algorithms point to a broader platform story. However, with a delayed 10 Q filing and debt heavy funding, investors who want exposure to this kind of IPO momentum need to consider how much balance sheet risk they are willing to accept.

AI powered cancer tests, fresh licensing deals and a tiny US$10.2m market cap make 20/20 Biolabs look like an overlooked early bet, but the 1 key reward and 5 important warning signs (2 are major!) could change how you see its funding clock and volatility risk

The three IPO stocks in this article are just a starting point, with the full IPO Momentum Stocks filter on Simply Wall St surfacing 7 more companies that pair recent gains with equally compelling post listing stories inside the IPO Momentum Stocks screener. Use the screener to identify and analyze the specific catalysts and narratives that matter to you so you can focus on the highest conviction opportunities in this corner of the market.

Take Control of Your Investment Journey

If PicS or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Curious About What You Might Be Missing?

Fresh IPOs are not the only stocks building quiet momentum. Some themes move fast, and the best entries can be caught before the crowd even looks, so consider acting early.

• Spot potential breakouts in smaller companies that already carry solid balance sheets and fundamentals by scanning the list of solid balance sheet and fundamentals (48 results) before others catch on.
• Track income focused stocks that pair higher yields with resilience by reviewing the curated 8 dividend fortresses while prices and payouts still look aligned.
• Zero in on fast evolving AI themes beyond the headlines by checking the hand picked 48 AI infrastructure stocks while the story is still under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.